Publications
518 results found
Igakura T, Stinchcombe JC, Goon PKC, et al., 2003, Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton, SCIENCE, Vol: 299, Pages: 1713-1716, ISSN: 0036-8075
- Author Web Link
- Cite
- Citations: 547
Lyall EGH, Taylor GP, Clarke J, et al., 2003, Polymerase chain reaction diagnosis of human immunodeficiency virus infection, PEDIATRIC INFECTIOUS DISEASE JOURNAL, Vol: 22, Pages: 295-295, ISSN: 0891-3668
- Author Web Link
- Cite
- Citations: 3
Asquith BE, Mosley AJ, Goon PK, et al., 2003, Does the CTL response determine HTLV-I equilibrium proviral load?, 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S38-S38, ISSN: 0889-2229
Goon PK, Taylor GP, Bangham CR, 2003, HTLV-I-specific CD4+ T cells: Immunodominance hierarchy and preferential infection with HTLV-I., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S9-S9, ISSN: 0889-2229
Nejmeddine M, Barnard AL, Goon P, et al., 2003, Mechanisms involved in the spread of HTLV-1 between lymphocytes., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S37-S37, ISSN: 0889-2229
Igakura T, Stinchcombe JC, Goon PK, et al., 2003, HTLV-I spreads between lymphocytes by virus-induced polarization of the cytoskeleton., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S15-S15, ISSN: 0889-2229
Davison KL, Vickers M, Hewitt P, et al., 2003, HTLV-I and II in blood donors in England and Wales: The experience so far., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S36-S37, ISSN: 0889-2229
Ruckes T, Clarke J, Laue T, et al., 2003, Accurate determination of HTLV proviral load by a multiplex one-tube real-time PCR quantitation assay., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S55-S55, ISSN: 0889-2229
Taylor GP, Goon P, Usuku K, et al., 2003, The bridge study - A double-blind placebo controlled trial of zidovudine plus lamivudine for treatment of patients with HTLV-I-associated myelopathy., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S13-S14, ISSN: 0889-2229
- Author Web Link
- Cite
- Citations: 2
Payne LJ, Tosswill JH, Taylor GP, et al., 2003, HTLV I and II infections in England and Wales 1988-2001., 11th International Conference on Human Retrovirology: HTLV and Related Viruses, Publisher: MARY ANN LIEBERT INC PUBL, Pages: S35-S35, ISSN: 0889-2229
Prime KP, Sethi G, Navaratne L, et al., 2002, Differences in presentation and follow up between HIV-1 antibody positive teenagers and older adults: The need for a more focused approach to care, AIDS, Vol: 17, Pages: 260-262
Wimalasundera RC, Larbalestier N, Smith JN, et al., 2002, Pre-eclampsia, antiretroviral therapy, and immune reconstitution, LANCET, Vol: 360, Pages: 1152-1154, ISSN: 0140-6736
- Author Web Link
- Cite
- Citations: 139
Pennington J, Taylor GP, Sutherland J, et al., 2002, Persistence of HTLV-I in blood components after leukocyte depletion, BLOOD, Vol: 100, Pages: 677-681, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 39
Goon PKC, Hanon E, Igakura T, et al., 2002, High frequencies of Th1-type CD4<SUP>+</SUP> T cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, BLOOD, Vol: 99, Pages: 3335-3341, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 75
Littleton ET, Man WD, Holton JL, et al., 2002, Human T cell leukaemia virus type I associated neuromuscular disease causing respiratory failure, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 72, Pages: 650-652, ISSN: 0022-3050
- Author Web Link
- Cite
- Citations: 16
Taylor GP, Jungmann E, Mercey D, 2002, Hepatoxicity with antiretroviral treatment of pregnant women., Obstet Gynecol, Vol: 99, Pages: 842-843, ISSN: 0029-7844
Dean GL, Edwards SG, Ives NJ, et al., 2002, Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy, AIDS, Vol: 16, Pages: 75-83, ISSN: 0269-9370
- Author Web Link
- Cite
- Citations: 252
Taylor GP, Jungmann E, Mercey D, 2002, Hepatoxicity with antiretroviral treatment of pregnant women, Obstetrics and Gynecology, Vol: 99, Pages: 842-843, ISSN: 0029-7844
Jungmann EM, Mercey D, DeRuiter A, et al., 2001, Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities?, SEXUALLY TRANSMITTED INFECTIONS, Vol: 77, Pages: 441-443, ISSN: 1368-4973
- Author Web Link
- Cite
- Citations: 35
Man WD, Littleton ET, Taylor GP, et al., 2001, Respiratory muscle weakness in HTLV-1 associated myopathy, THORAX, Vol: 56, Pages: 48-48, ISSN: 0040-6376
Taylor GP, 2001, The human T-lymphotropic viruses: bench and bedside progress, VIRUS RESEARCH, Vol: 78, Pages: 1-4, ISSN: 0168-1702
- Author Web Link
- Cite
- Citations: 2
Lyall EG, Blott M, de Ruiter A, et al., 2001, Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission., HIV Med, Vol: 2, Pages: 314-334, ISSN: 1464-2662
AIMS OF THE GUIDELINES: These guidelines, drawn up by a multidisciplinary group of clinicians and lay workers active in the management of pregnant women infected with HIV, aim to give up-to-date information on interventions to reduce the risk of mother to child transmission of the virus. The evidence on the use of interventions to prevent mother to child transmission of HIV has been graded according to the strength of the data as per the definitions of the US Agency for Health Care Policy and Research [1]. Weighted evidence on the use of combination antiretroviral therapy (ART) for the treatment of HIV infection per se is presented in the BHIVA guidelines for adults [2,3]. The highest level evidence (i.e. randomised controlled trials (RCTs) or large, well conducted meta-analyses) is only available for formula feeding, prelabour caesarean section and zidovudine monotherapy. The need to treat mothers for HIV infection has led to the widespread use of ART in pregnancy which in turn results in new questions such as how to deliver when the mother, on therapy, has no detectable plasma viraemia with the most sensitive assays. In addressing many common and/or difficult clinical scenarios in the absence of 'best evidence' the guidelines rely heavily on 'expert opinion'. Recommendations for management are given in the section on clinical scenarios, and summarized in Table 3. An expanded version of these guidelines with an appendix on safety and toxicity data is available on the BHIVA website http://www.bhiva.org. The authors are available to discuss individual cases.
Andersson S, Gessain A, Taylor GP, 2001, Pooling of samples for seroepidemiological surveillance of human T-cell lymphotropic virus types I and II, VIRUS RESEARCH, Vol: 78, Pages: 101-106, ISSN: 0168-1702
- Author Web Link
- Cite
- Citations: 28
Taylor GP, 2001, Abstracts of the HTLV European Research Network meeting, Potsdam, Germany 19-21st May 2000, VIRUS RESEARCH, Vol: 78, Pages: 107-129, ISSN: 0168-1702
Hanon E, Goon P, Taylor GP, et al., 2001, High production of interferon γ but not interleukin-2 by human T-lymphotropic virus type I-infected peripheral blood mononuclear cells, BLOOD, Vol: 98, Pages: 721-726, ISSN: 0006-4971
- Author Web Link
- Cite
- Citations: 74
Goon PKC, Watkins RPF, Lyall EGH, et al., 2001, Third trimester screening or safer sex to prevent mother to child transmission of HIV [9], Sexually Transmitted Infections, Vol: 77, Pages: 226-227, ISSN: 1368-4973
- Cite
- Citations: 2
Goon PKC, Watkins RPF, Lyall EGH, et al., 2001, Third trimester screening or safer sex to prevent mother to child transmission of HIV, SEXUALLY TRANSMITTED INFECTIONS, Vol: 77, Pages: 226-227, ISSN: 1368-4973
- Author Web Link
- Cite
- Citations: 2
Matutes E, Taylor GP, Cavenagh J, et al., 2001, Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma:: response and outcome in 15 patients, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 113, Pages: 779-784, ISSN: 0007-1048
- Author Web Link
- Cite
- Citations: 74
Thorne C, Newell ML, Gray L, et al., 2001, HIV-infected pregnant women and vertical transmission in Europe since 1986, AIDS, Vol: 15, Pages: 761-770, ISSN: 0269-9370
- Author Web Link
- Cite
- Citations: 133
Edwards SG, Larbalestier N, Hay P, et al., 2001, Experience of nevirapine use in a London cohort of HIV-infected pregnant women., HIV Med, Vol: 2, Pages: 89-91, ISSN: 1464-2662
OBJECTIVE: To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome. METHODS: We identified all HIV-1-infected women who received NVP as part of a triple antiretroviral regimen during pregnancy between January 1997 and September 1999. Laboratory results, clinical events, side-effects and pregnancy outcome were abstracted using a standardized proforma from the medical records. RESULTS: Forty-six women were identified, 85% of whom were black African. At initiation of NVP, the median age was 29 years and the median baseline CD4 cell count and viral load were 242 cells/microL and 4.15 log10 copies/mL, respectively. Thirty-two out of 36 women who had a plasma sample obtained at, or just prior to, delivery had an undetectable viral load (< 50 to < 400 copies/mL). Adverse events that were definitely attributed to NVP included a generalized rash (n = 2) and hepatitis (n = 2). Obstetric complications occurred in nine women (19.5%), which was not statistically different (P = 0.36) from that found in a historical (1990-96) control group 7/51 (14%). The rate of preterm delivery (13%) was similar to that previously reported in HIV-1 infected pregnant women (18%). CONCLUSIONS: NVP (as part of highly active antiretroviral therapy) reduced plasma viraemia to below the limit of detection in 89% of women. It was generally well tolerated and clinical and laboratory adverse events were infrequent. There was no evidence of an increase in obstetric complications including preterm delivery during the second and third trimesters of pregnancy.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.